Democratic Republic of Congo Begins Ervebo Vaccination Campaign Amid Record Ebola Outbreak

This outbreak is the fastest-growing in history, highlighting vulnerabilities in global health systems and the urgent need for effective response mechanisms.

• On August 27, 2026, the Democratic Republic of Congo launched a vaccination campaign using the Ervebo vaccine in Kisangani.
• Over 5,700 confirmed cases and approximately 2,744 deaths have been reported, marking this outbreak as the deadliest in Congo's history.
• The campaign prioritizes frontline health workers and response personnel, with 70,000 doses allocated under a compassionate-use protocol.

• The Bundibugyo virus strain is responsible for this outbreak, and no licensed vaccine or treatment exists specifically for it.
• The epidemic has spread across six provinces, exacerbated by factors such as insecurity, health worker strikes, and misinformation.
• Previous Ebola outbreaks in Congo have been contained, but this one is on track to potentially exceed the 2014-2016 West Africa outbreak in terms of fatalities.

The Democratic Republic of Congo's current Ebola outbreak, declared on May 15, 2026, is unprecedented in its rapid spread and severity. The Bundibugyo strain, which has no approved vaccine or treatment, has led to a staggering number of cases and deaths, with government figures reporting 5,713 confirmed cases and a case fatality rate of approximately 48%. This situation has prompted the government to act swiftly, receiving 70,000 doses of the Ervebo vaccine, which is licensed for the Zaire ebolavirus but is being used under a compassionate-use protocol to combat this outbreak.

Health Minister Roger Kamba launched the vaccination campaign in Kisangani, focusing on frontline health workers and response personnel. The initial rollout prioritizes over 50,000 doses for these workers, while approximately 20,000 doses are allocated for Phase 3 clinical trials to assess the vaccine's efficacy against the Bundibugyo strain. This dual approach aims to protect those most at risk while simultaneously gathering critical data on the vaccine's performance.

The outbreak's rapid escalation has been fueled by a combination of delayed detection, overwhelmed surveillance systems, and ongoing military conflict in the region. Health worker strikes and community displacement have further complicated response efforts, leading to misinformation and panic among the population. As the epidemic spreads across six provinces, the government, in coordination with the World Health Organization (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC), is focusing on ring vaccination strategies to contain the virus.

Despite the urgency of the situation, no significant market shifts or economic impacts have been reported as of late August 2026. Local responses are concentrated on expanding vaccination coverage and addressing operational challenges, including insecurity and resource constraints. The situation remains fluid, and the effectiveness of the vaccination campaign will be closely monitored as authorities aim to curb the outbreak's trajectory.

• Frontline health workers: They are at the highest risk of exposure and are prioritized for vaccination.
• Local communities: Residents in affected provinces face health risks and potential economic disruptions.
• International health organizations: They may need to adjust strategies and resources in response to the outbreak's developments.

• Vaccination coverage rates: Monitoring how quickly and effectively the Ervebo vaccine is administered will indicate the campaign's success.
• Case fatality rates: Changes in the number of deaths relative to confirmed cases will provide insight into the outbreak's severity and the vaccine's effectiveness.
• International response: Watch for potential shifts in global health policies or funding aimed at addressing similar outbreaks in the future.